日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / China-US

New medicine for prostate cancer available in China

chinadaily.com.cn | Updated: 2019-11-28 16:49
Share
Share - WeChat

New medicine to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC) is available in China to save those at high risk of developing metastases.

The Xian Janssen Pharmaceutical Ltd announced on Wednesday that ERLEADA (apalutamide) was put on the market in China after being granted by the China National Medical Products Administration (NMPA) in September, recognizing the urgent unmet need for patients with nmCRPC who currently have few treatment options.

ERLEADA is an androgen receptor inhibitor that works by preventing androgen from binding to the androgen receptor. It has been shown to delay the time to distant metastasis. Treatment with ERLEADA has also shown to result in the control of Prostate-Specific Antigen (PSA) levels, which is an important indicator during the early treatment and prognosis of patients with prostate cancer.

According to Professor Zhou Liqun, Head of Urology Department in Peking University First Hospital, the five year survival rate for advanced mCRPC patients is only 3% before the new method of endocrine treatment. "This rate increased to only 30% even with new treatment. So it is urgent to postpone progression and to maintain quality of life for patients living with nmCRPC and the approval of ERLEADA presents a new treatment option that can potentially addres this treatment.

The incidence rate of prostate cancer in China has increased and become one of the top five of the most common male cancers in the country over the past decade. The androgen-deprivation therapy (ADT) is the current standard of care for nmCRPC. However, if after initial sustained treatment with ADT, the cancer cells continue to progress without distant metastasis, patients will enter a stage called nmCRPC. Without interventions, 90% of patients with nmCRPC will eventually develop bone metastases, which can lead to pain, fractures and spinal cord compression.

According to data from a clinical study, ERLEADA reduced the risk of advanced metastasis or death by 72% and increased median metastasis-free survival by over two years among patients with nmCRPC who are undergoing continuous ADT treatment.

Professor Wang Jianye, Dean of Beijing Hospital and Director of National Center of Gerontology, said "In recent years, urology and oncology doctors are working on new NM-CRPC treatment and medicine. ERLEADA optimizes the standard NM-CRPC treatment in China and provides quality time for patients and their families."

"As one of the leading pharmaceutical companies in China, Xian Janssen has been dedicated to helping patients with prostate cancer in China. We recognize the varied needs of patients across all stages of prostate cancer, which require collaborative efforts from government, society and the healthcare industry to address. To help patients with prostate cancer receive better treatment, we are committed to exploring the full potential of our solutions in addressing unmet treatment needs across all stages of disease progression," said Asgar Rangoonwala, President of Xian Janssen.

ERLEADA is now available in major Chinese cities including Beijing, Shanghai, Guangzhou and Tianjin. Xian Janssen is supporting the China Primary Healthcare Foundation to launch a Patient Access Program that helps low-income patients in China access treatment with ERLEADA.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 夜夜视频 | 成人毛片久久 | 亚洲一区二区三区四区精品 | 日本最新中文字幕 | 妞干在线 | 香蕉久久a毛片 | 狠狠一区 | 天天操网 | 日韩2区 | 日韩精品免费视频 | 爱豆在线观看网址91 | 免费 | 日本黄色片免费看 | 成年人福利 | 日韩有码第一页 | 亚洲综合国产 | 99视频网站| 天天草天天爱 | 五月婷婷 六月丁香 | 高清videosgratis欧美live | 天天色综合久久 | 亚洲五月婷 | 久操久操| 久久精品蜜芽亚洲国产a | gogo全球大胆高清人露出91 | 成人网页| 亚洲精品乱码久久久久久久久久 | 麻豆国产一区二区三区四区 | 国产福利在线观看永久免费 | 亚洲12p| 色婷婷香蕉| 成人国产在线观看 | 久久噜噜噜精品国产亚洲综合 | 午夜伦4480yy私人影院 | 亚洲精品老司机综合影院 | 中文字幕在线精品 | 亚洲人成网站999久久久综合 | 成人不卡在线 | 精品在线播放 | 午夜剧场直接免费观看 | 久久久国产一级片 | 五月婷婷精品 |